Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dropping fast Offering Coming !
The offering is expected to close on July 18, 2017
The offering is expected to close on July 18, 2017
Great Short Here $9.40 Offering coming !
9k out today
The price to the public in the Offering is $10.00 per share, and the Underwriters have agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $9.40 per share
* * $ALDR Video Chart 07-13-17 * *
Link to Video - click here to watch the technical chart video
Almost ready to buy. Many thanks to the overreactors!!!
Hope it goes under 11. Pick up some dxtr, and monitoring dcth for a buy in.
good trade what do you think it will do
I sold that same day for $15, which was way too early
took 13.70 long for a trade
Valuation analyses show Alder Biopharmaceuticals is highly undervalued... Earnings today to be the catalyst?
Analysis
Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine
https://finance.yahoo.com/news/alder-reports-positive-top-line-120000216.html
Investor 100
Nice 6% gainer today!!!
Going much higher!
Investor 100
Alder Presents Preclinical Data for ALD1613 at ENDO 2016
-ALD1613 Administration Reduces Plasma Corticosterone in Multiple Preclinical Models-
http://finance.yahoo.com/news/alder-presents-preclinical-data-ald1613-171500565.html
Key Points:
In vitro, ALD1613 inhibits ACTH-induced cortisol secretion in a mouse adrenal cell line.
ALD1613 administration in rats with artificially elevated ACTH and corticosterone levels resulted in a rapid and durable reduction of plasma corticosterone levels.
In non-human primates, ALD1613 demonstrated stable and durable reductions in plasma cortisol levels by >50%.
Randall C. Schatzman, Ph.D., President and Chief Executive Officer of Alder, said, “Existing therapeutic options for patients with congenital adrenal hyperplasia and Cushing's disease comprise treatments that provide limited disease control and involve significant side effects. We believe these limitations indicate a clear need for new therapies such as ALD1613, which targets ACTH to diminish the overproduction of cortisol. The data presented today demonstrate the capacity of ALD1613 to reduce corticosteroid levels in preclinical settings. We intend to use these studies as part of an IND filing that we plan to submit to the FDA in the second half of 2016.”
Investor 100
Our March highlight just gained 50%: Alder Biopharmaceuticals
http://marketexclusive.com/our-march-highlight-just-gained-50-alder-biopharmaceuticals-inc-nasdaqaldr/4872/
Monster Run On Huge News Up 57%
http://seekingalpha.com/news/3169667-alder-bios-migraine-candidate-ald403-successful-mid-stage-study-shares-9-percent-premarket
Investor 100
Alder is a Risky Allocation in a Crowded, but Rewarding Space
http://marketexclusive.com/alder-is-a-risky-allocation-in-a-crowded-but-rewarding-space/2587/
Cramer @ ALDR
Looking forward to the Phase 3 results!
Buying the dip as well...
http://www.thestreet.com/story/13393479/1/jim-cramer-s-top-takeaways-alder-biopharmaceuticals-ensco.html?puc=yahoo&cm_ven=YAHOO
Alder BioPharmaceuticals (ALDR) : For his "Executive Decision" segment, Cramer spoke with Dr. Randall Schatzman, president and CEO of Alder BioPharmaceuticals, a stock that rallied over 11% in today's session but still remains 48% from its 2015 highs.
Schatzman said while it's been a wild week on Wall Street, the biopharmaceutical space has never been stronger. There is more innovation and more drugs being approved than ever.
When asked about his company's migraine treatment, which is currently in Phase III testing, Schatzman said the company believes it has identified and neutralized one of the primary factors that trigger migraines. So far, patients are responding well in the study. He said Alder has been successful using social media to spread the word to the 36 million migraine sufferers out there.
Schatzman was also upbeat on his company's arthritis drug, which will be entering Phase III trials soon.
Cramer said the best time to buy these stocks is when they're hated, not when they're loved.
ALDR @ JPMorgan Healthcare Conference Presentation
http://files.shareholder.com/downloads/AMDA-2K5VML/1355915823x0x869777/F50353BF-AD37-4358-9D66-D4B10F92ADC6/JPM_2016_Presentation_Present_FINAL.pdf
Investor 100
Migraine Statistics
In the U.S., more than 37 million people suffer from migraines. Some migraine studies estimate that 13 percent of adults in the U.S. population have migraines, and 2-3 million migraine suffers are chronic.
Almost 5 million in the U.S. experience at least one migraine attack per month, while more than 11 million people blame migraines for causing moderate to severe disability.
One study estimates the loss of productivity in the U.S. to be between $5.6 billion to $17.2 billion per year because of missed work. The average migraine sufferer misses two days of work per year. Some who suffer from persistent migraines work during a migraine attack, which they say lowers productivity. It is estimated that migraines are the reason for 36 million days of bed rest, plus 21.5 million days of restricted activity.
https://migraine.com/migraine-statistics/
Investor 100
CEO @ ALDR Interview
Like the story here with ALDR!
CEO @ Mad Money
CEO provided some guidance in 2016 on Mad Money last evening that I think was positive news ( Migrane - Phase 3 )....like the tone and opportunity here!
Investor 100
Here is What Hedge Funds Think About Alder Biopharmaceuticals Inc (ALDR)
heck yes...doubled up my position on the dip!
Is Alder Biopharmaceuticals Inc (NASDAQ:ALDR) a buy here? Money managers are taking a bullish view. The number of bullish hedge fund positions went up by 5 recently. ALDR was in 23 hedge funds’ portfolios at the end of September. There were 18 hedge funds in our database with ALDR holdings at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks.
Investor 100
http://www.insidermonkey.com/blog/here-is-what-hedge-funds-think-about-alder-biopharmaceuticals-inc-aldr-392542/
ALDR @ Stockcharts
Like to movement and indicators..bought the dip..moving much higher!
http://www.thestreet.com/video/13317423/migraine-drug-results-will-cure-stock-headache-says-alder-ceo.html?puc=yahoov&cm_ven=YAHOOV
Investor 100
Upward @ ALDR
Nice bounce today with a 2.37% gain!
Investor 100
Dip @ ALDR
Like the dip...bought a few more shares!
Investor 100
Upward @ ALDR
LIke the 2.59% gainer today...buying on dips...
Investor 100
Added @ ALDR
Added a few nore shares on the dip!
Investor 100
Steady @ ALDR
More room for growth with a 1.61% gain!
http://www.alderbio.com/therapeutics/pipeline/
http://www.thestreet.com/story/13176848/1/jim-cramer-says-alder-biopharmaceuticals-aldr-is-meeting-gigantic-unmet-needs.html
Investor 100
Zacks @ ALDR
Alder Biopharmaceuticals Inc. (ALDR) in Focus: Stock Soars 12.9% - Tale of the Tape
http://finance.yahoo.com/news/alder-biopharmaceuticals-inc-aldr-focus-131801881.html
Investor 100
Stock Issue @ ALDR
I was concered with this news but the fact of the matter is the stock is up afterwards and today when the market was down 35) points this stock was up over 2.85%!
Alder Biopharmaceuticals (ALDR) Stock Rises After Pricing Secondary Offering
http://www.thestreet.com/story/13200800/1/alder-biopharmaceuticals-aldr-stock-rises-after-pricing-secondary-offering.html?puc=yahoo&cm_ven=YAHOO
Investor 100
Added @ ALDR
Nice dip to add more shares- like the story and CEO interview on CNBC!
Alder BioPharmaceuticals Announces Commencement of Public Offering of Common Stock
http://finance.yahoo.com/news/alder-biopharmaceuticals-announces-commencement-public-200100715.html
Upward @ ALDR
Buying more on the dip!
Alder Bio Up As Credit Suisse Lauds Migraine Drug
http://news.investors.com/062415-758806-aldr-stock-hits-high-on-credit-suisse-report.htm?ven=yahoocp&src=aurlled&ven=yahoo
Investor 100
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
58
|
Created
|
04/13/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |